Balyasny Asset Management L.P. Boosts Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Balyasny Asset Management L.P. boosted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 277.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 80,743 shares of the company’s stock after purchasing an additional 59,334 shares during the quarter. Balyasny Asset Management L.P.’s holdings in Ginkgo Bioworks were worth $793,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Forbes J M & Co. LLP raised its position in Ginkgo Bioworks by 461.4% during the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock worth $6,891,000 after buying an additional 576,732 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Ginkgo Bioworks during the 4th quarter worth approximately $29,000. Barclays PLC raised its position in Ginkgo Bioworks by 353.6% during the 4th quarter. Barclays PLC now owns 54,166 shares of the company’s stock worth $531,000 after buying an additional 42,224 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Ginkgo Bioworks by 65.1% during the 4th quarter. Renaissance Technologies LLC now owns 114,654 shares of the company’s stock valued at $1,126,000 after purchasing an additional 45,200 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Ginkgo Bioworks during the 4th quarter valued at approximately $199,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Price Performance

NYSE:DNA opened at $7.79 on Thursday. The firm has a market cap of $452.08 million, a price-to-earnings ratio of -0.60 and a beta of 1.29. The company has a 50 day moving average price of $7.14 and a 200-day moving average price of $9.07. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.00 and a 1-year high of $37.26.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The company had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. On average, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.